EBV-CTL (Atara/MSKCC)

N/A

Report date: 2023/04/23 15:25:37

Base Information

Drug NameEBV-CTL (Atara/MSKCC)
Drug Alias NameEBV-CTL-Atara-MSKCC
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics IncMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoproliferative Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A